Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
First, we emulated two cardiovascular outcome trials, SUSTAIN-6 (semaglutide versus sitagliptin as placebo proxy) and SURPASS-CVOT (tirzepatide versus dulaglutide), to benchmark and critically evaluate our design, data and analytic framework
Gallbladder disease: Cholelithiasis (gallstones) and cholecystitis have been reported with GLP-1-based therapies, likely related to rapid weight loss
Semaglutide is an FDA-approved injectable drug that is used to treat type 2 diabetes mellitus
DSIPs molecular mechanisms remain an active area of investigation
US$ 27.90
US$ 20.70
US$ 25.04
US$ 24.62
US$ 20.99
